Base-edited CAR T-cell therapy shows promise for relapsed, refractory childhood ALL

Base-edited chimeric antigen receptor T-cell therapy is feasible for the treatment of relapsed or refractory childhood T-cell acute lymphoblastic leukemia, suggests research published in The New England Journal of Medicine.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.